ARA-290 Australia: Buy ARA-290 Online

Shop ARA-290 as a 10 mg Vial With Full Lot Data

Order ARA-290 when a study needs the tissue-protective signalling of EPO on its own, separated from blood cell formation. Few suppliers carry this EPO-derived peptide, and ours ships from Australian stock with its lot data already published.

What Is ARA-290 (Cibinetide)?

ARA-290, also called cibinetide, is a small synthetic peptide modelled on one surface of erythropoietin (EPO) that switches on EPO's tissue-protective signalling while leaving its red blood cell signalling untouched. Put plainly, it is a piece of a well known hormone, redesigned so that only one of the hormone's two jobs remains.

How the ARA 290 peptide works in research models

EPO is a glycoprotein folded into four alpha helices, labelled A to D. Three of them do the work of gripping the classical EPO receptor pair that drives red cell production in bone marrow. Helix B points away from that receptor, out into the surrounding fluid, which is why Michael Brines and his co-workers suspected it carried the separate protective message. Their target was the innate repair receptor, a complex that cells assemble when they are stressed, starved of oxygen or inflamed, pairing one EPO receptor chain with the CD131 subunit. EPO binds this complex far more weakly than its classical partner, so earlier efforts to exploit tissue protection with whole EPO needed high concentrations that also pushed up red cell output. A short helix B mimic sidesteps that trade-off, and in the models reported it reduced inflammatory cytokine signalling and cell death after ischaemic, toxic or nerve injury.

• Class: linear 11-residue peptide with a cyclised N-terminal residue.
• Target: EPO receptor and CD131 heterocomplex, upregulated after injury.
• Pharmacokinetics: a short plasma half-life, with effects in models outlasting the peptide's presence in blood.
• Development: Araim Pharmaceuticals took it through phase 2, and no phase 3 trial has been completed.

The strongest clinical dataset is a 28-day randomised phase 2b study of 64 participants with sarcoidosis-associated small nerve fibre loss and neuropathic pain, published by Culver, Dahan and colleagues in 2017. Corneal nerve fibre area, measured by corneal confocal microscopy, rose significantly against placebo in one of the three active arms, and skin biopsies in that arm showed more regenerating GAP-43 positive fibres. The other two arms did not separate from placebo, so the result is encouraging but not a clean dose relationship.

Our view for lab planning: cibinetide is only informative in a system that actually expresses CD131. Many cell lines carry the EPO receptor but little beta-common subunit until they are stressed, so build an injury or cytokine challenge into the protocol and confirm CD131 by blot or PCR before reading a negative result as a failed peptide.

Buy ARA-290 Australia Stock to Isolate the Innate Repair Receptor

Erythropoietin signals through two receptor arrangements. The classic EPO receptor homodimer on erythroid progenitors drives red blood cell production, while a second complex, the EPO receptor paired with the beta-common receptor CD131, appears to mediate tissue protection. Michael Brines, Anthony Cerami and colleagues traced that protective activity to the helix B face of EPO and built a short linear peptide around it, later developed by Araim Pharmaceuticals as cibinetide.

Buy it for clean separation, an agonist of the innate repair receptor that, in the models reported, leaves haematopoiesis alone. Cibinetide has been examined in early clinical studies overseas, yet it is not registered as a medicine in Australia and is sold here as a research reagent. It sits in our recovery peptides category.

Is ARA-290 Available in Australia? Cibinetide's Status and the Vial Itself

The material we stock is a single 10 mg glass vial of lyophilised cibinetide, a small white cake with no diluent and no second peptide alongside it. It is the only EPO-derived compound in our range, and it shares nothing structurally with the gastric or thymic peptides that sit beside it in the recovery category. The sequence was described in a 2008 PNAS paper from the Brines and Cerami group, which built short non-erythropoietic peptides from the three-dimensional structure of erythropoietin and later took this one into development.

Overseas, cibinetide has gone into small phase 2 clinical studies, most notably in small fibre neuropathy linked to sarcoidosis and in painful neuropathy with type 2 diabetes. None of that work has produced an approved medicine. As of October 2026 no regulator, the TGA included, has approved cibinetide for sale, and no product containing it appears on the ARTG, so there is no prescription pathway through a pharmacy for ARA-290 Australia searchers to find. Sport is the other place it turns up: WADA prohibits innate repair receptor agonists under S2.1 at all times, and earlier editions of the list named ARA-290 as an example, a rule Sport Integrity Australia enforces locally.

Because the drug candidate never reached registration anywhere, cibinetide in Australia exists only as a research chemical. Labs who buy ARA-290 in Australia from AminoBlend receive it from vials held here in local stock, sold as a laboratory reagent to adults 18 and over, with no human or veterinary use permitted. Before ordering, check the pyroglutamate mass on the matching report in our COA library, and see the wider tissue repair peptide range for compounds that act through other receptors.

Order ARA-290 Peptide in One 10 mg Vial, Lot Tracked

Cibinetide comes in one fill, the 10 mg vial at $89.99, close to $9.00 per mg. The price reflects a longer synthesis that ends with the cyclised N-terminal pyroglutamate. At about 1257 g/mol, a vial holds roughly 8 micromoles, plenty for a receptor assay or a pilot cell culture series. Molar terms matter when you set ARA-290 against EPO in the same experiment, since the peptide is a small fraction of the glycoprotein's mass.

Shop one vial first to confirm your system responds, then order the rest of the series together so every run traces back to one lot wherever stock allows and one certificate. Sales are limited to adults aged 18 or older, who state their research purpose at checkout.

Shop ARA-290 Australia Lots With Structure and Purity on File

Two details deserve a look on the certificate. The measured mass should sit near 1257.3 g/mol, and the first residue should be pyroglutamate rather than open glutamine, a difference of about 17 mass units that reveals an incomplete cyclisation. The chain carries two glutamates, one arginine and an uncharged pyroglutamate start, leaving a net charge of about minus two at neutral pH, which shapes its HPLC retention.

Buy after opening the purity result and chromatogram, which sit on the same report, by lot code in our certificate archive. Our guide to reading a COA walks through each line of that report.

Why insist on these checks for a newer catalogue compound? Peptides with a short commercial history attract more poorly made material, and an open-chain glutamine variant or a truncated sequence would look identical as a white powder. A lot-matched report removes that doubt before the vial reaches your bench, and the lot code lets you cite exactly which material you used when the data are written up.

Order Cibinetide Online From Anywhere in Australia and Store the Vial

Every ARA-290 order goes through this online store, which supplies labs nationwide, including those buying research peptides in Canberra, from one Australian stock with no walk-in counter. If you order before 3pm on a business day, the vial is dispatched that afternoon with tracking, and progress can be followed on the track order page.

Buy bacteriostatic water in the same cart. Warm the vial to room temperature, add the diluent slowly down the glass and swirl until clear. Adding 2 mL to the 10 mg vial yields 5 mg/mL, and the concentration calculator handles other volumes.

Unopened vials are best kept frozen at -20 °C, protected from light. After reconstitution, refrigerate the solution at 2 to 8 °C in portions and do not refreeze it.

Other Names for ARA-290

The compound is listed as ARA-290, ARA 290, ARA290 and cibinetide, its international nonproprietary name, and sometimes as helix B surface peptide or pHBSP, the pyroglutamate form described in early papers. Each name refers to the 11-residue chain with CAS 1208243-50-8.

Receptor terms come with it, among them innate repair receptor (IRR), tissue-protective receptor, EPOR, CD131 and beta-common receptor. The peptide should not be confused with EPO itself or with erythropoiesis-stimulating agents.

Buy ARA-290 or KPV for Anti-Inflammatory Signalling Work

Both are short peptides pulled from larger hormones and studied for anti-inflammatory signalling, but they work through different doors. ARA-290 targets the EPO receptor and CD131 complex, while KPV, the alpha-MSH tripeptide at $59, enters epithelial cells through PepT1 and damps NF-kappa B. Pick ARA-290 for receptor-level tissue protection work and KPV for gut and skin epithelium models.

Order BPC-157 for a third angle on repair, covering growth factor and nitric oxide pathways in rodent injury models. Running two or three of these compounds side by side, each from its own vial, lets a study map which pathway carries an effect rather than guessing from a single reagent. ARA-290 Australia buyers often set up exactly that kind of panel.